20/20 Biolabs, Inc. (AIDX) disclosed it received a non-compliance notice from Nasdaq for failing to maintain a minimum $1.00 bid price. Concurrently, the company entered into a 120-day standstill agreement with investor Streeterville Capital, LLC to temporarily halt the conversion of its Series E convertible preferred stock, providing stability while it addresses the listing requirements.
Key Details
- Nasdaq Non-Compliance: The notice, received on July 17, 2026, was triggered by the company's stock closing below $1.00 for 30 consecutive business days (from June 3 to July 16, 2026).
- Compliance Period: AIDX has been granted a 180-day compliance period, until January 13, 2027, to regain compliance by having its closing bid price meet or exceed $1.00 for at least 10 consecutive business days.
- Standstill Agreement: Effective July 16, 2026, Streeterville Capital agreed not to convert its Series E preferred shares for 120 days. This restriction is lifted if AIDX's common stock trades at a price at least 10% greater than the Nasdaq-defined "Minimum Price".